CYT 013 IL1bQb

Drug Profile

CYT 013 IL1bQb

Alternative Names: CYT013-IL1bQb

Latest Information Update: 31 Aug 2011

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Antihyperglycaemics; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 17 Aug 2011 Suspended - Phase-I/II for Type-2 diabetes mellitus in Germany (SC)
  • 17 Aug 2011 Suspended - Phase-I/II for Type-2 diabetes mellitus in Switzerland (SC)
  • 11 Jun 2009 Phase-I/II clinical trials in Type-2 diabetes mellitus in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top